Disease/Infection News

RSS

Recent release: Kaiser Family Foundation releases report comparing AIDS responses of U.S., other high-income countries

The Kaiser Family Foundation on Tuesday released a report titled, "Responding to AIDS at Home & Abroad: How the U.S. and Other High-Income Countries Compare," which "examines the United States' response to HIV over the last 30 years compared to ... seven other similarly situated nations -- Australia, Canada, France, the Netherlands, Sweden, Switzerland and the United Kingdom," according to the report's webpage.

26 Jul 2012

Children missing out on in battle against TB

The number of children diagnosed with tuberculosis only represents the tip of the iceberg, according to the University of Sydney’s Associate Professor Ben Marais, a specialist in childhood tuberculosis writing in the latest issue of The New England Journal of Medicine.

25 Jul 2012

Survey offers solutions to meet the needs of young people with HIV

Very few children are born with HIV in Thailand today. During the 1990s, the Thai government implemented a vast prevention programme in order to control the epidemic that was rife in the North of the country. The reduction of mother-to-child transmission was one of the major successes resulting from these measures. However, before this programme was established, numerous infants were born with the infection.

25 Jul 2012

Community health campaigns reduce incidence of HIV virus levels in rural Uganda

Population-wide levels of HIV virus dropped substantially between 2011 and May 2012 in a rural part of southwestern Uganda, the site of two community health campaigns led by doctors at the University of California, San Francisco (UCSF), San Francisco General Hospital and Trauma Center (SFGH) and Makerere University in Kampala, Uganda.

25 Jul 2012

Human neutrophil peptide 1 effectively prevents HIV entry into cells in multiple ways

Human defensins, aptly named antimicrobial peptides, are made in immune system cells and epithelial cells (such as skin cells and cells that line the gut). One of these peptides, human neutrophil peptide 1, under certain circumstances hinders HIV infection, but exactly how it works remains unclear.

25 Jul 2012

Devex examines history, future of PEPFAR

In a feature analysis, Devex examines the history of PEPFAR, the program's sustainability, its use of public-private partnerships, and the potential impact of the closure earlier this month of the Global Health Initiative (GHI) office.

25 Jul 2012

Drug resistance increasing in parts of Africa, report shows

"Resistance to AIDS drugs, a problem that has been widely feared over the last decade, is growing in parts of Africa but should not hamper the life-saving drug rollout, researchers reported on Monday" in a study published in the Lancet, Agence France-Presse reports.

25 Jul 2012

New combination therapy for TB shows promise in Phase II study

"Results from a groundbreaking trial of three drugs given in combination -- one of them completely new and one not yet licensed for this use -- killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.

25 Jul 2012

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

Fewer than 100 researchers nationwide are chosen each year to receive the Presidential Early Career Award for Scientists and Engineers (PECASE), and this year Dr. Nihal Altan-Bonnet is one of the 96 to receive this honor.

25 Jul 2012

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

A new grant from the National Institute of Allergy and Infectious Diseases (NIAID) will support the development of a topical microbicide gel for drug delivery. The innovative gel formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

25 Jul 2012

Merck signs two licensing agreements for investigational HIV drug candidates

Merck, known as MSD outside the United States and Canada, announced today that the company has signed two licensing agreements for investigational HIV drug candidates.

25 Jul 2012

Little evidence exists for potential HPV type competition in cross-sectional study

Vaccines against human papillomavirus (HPV) are now recommended by the Centers for Disease Control and Prevention for both teenage boys and girls. The vaccine protects against the two most common types of the virus that cause cervical cancer: HPV 16 and 18. Is there a chance that the increased number of people vaccinated might result in an increase of other types of HPV that cause cancer?

25 Jul 2012

Bill Gates stresses importance of investment in both HIV treatment and research for vaccines, microbicides

In a symposium session on Monday at the XIX International AIDS Conference in Washington, D.C., politicians and public health experts joined Bill & Melinda Gates Foundation Co-Chair Bill Gates for a discussion about improving effectiveness and efficiency in the HIV/AIDS response, the Washington Post reports.

25 Jul 2012

Researchers discover bats as reservoir of infections

Measles, mumps, pneumonia, influenza and encephalitis in man, Carré's disease in dogs, Ovine Rinderpest (PPR)… all of these diseases are caused by viruses from the same family: Paramyxoviridae. A vast international study, carried out in collaboration with IRD researchers and published in Nature communications has led to the discovery of more than 60 new species of these dangerous infectious agents, almost double the number previously recorded. This family of highly diverse pathogens affects all animals, from canines to fowl, cattle and humans.

25 Jul 2012

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

In a speech delivered at the XIX International AIDS Conference in Washington, D.C., on Monday, U.S. Secretary of State Hillary Clinton "underscored the United States' commitment to achieving an 'AIDS-free generation' and announced more than $150 million in additional funding," Politico reports.

25 Jul 2012

Dapivirine Phase III trial now underway in Africa to treat HIV in women

A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women - a vaginal ring used once a month - is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).

25 Jul 2012

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

A selection of editorials and op-eds from around the country that focus on the campaign to eradicate HIV.

25 Jul 2012

Insight into possible new approaches in vaccine development for blood-borne infections and HIV

White blood cells called neutrophils, which are the first line of defense against infection, play an unexpected role by boosting antibody production, according to research led by Mount Sinai School of Medicine. The findings suggest neutrophils have multiple roles within the immune system and function at levels previously unknown to the scientific community. The research, published in Nature Immunology, provides groundbreaking insight into possible new approaches in vaccine development for blood-borne infections and HIV.

25 Jul 2012

Scientists discover structure and operating procedures of anti-bacterial killing machine

Scientists have discovered the structure and operating procedures of a powerful anti-bacterial killing machine that could become an alternative to antibiotics.

25 Jul 2012

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.

24 Jul 2012

Disease/Infection News

Recent release: Kaiser Family Foundation releases report comparing AIDS responses of U.S., other high-income countries

Children missing out on in battle against TB

Survey offers solutions to meet the needs of young people with HIV

Community health campaigns reduce incidence of HIV virus levels in rural Uganda

Human neutrophil peptide 1 effectively prevents HIV entry into cells in multiple ways

Devex examines history, future of PEPFAR

Drug resistance increasing in parts of Africa, report shows

New combination therapy for TB shows promise in Phase II study

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

Merck signs two licensing agreements for investigational HIV drug candidates

Little evidence exists for potential HPV type competition in cross-sectional study

Bill Gates stresses importance of investment in both HIV treatment and research for vaccines, microbicides

Researchers discover bats as reservoir of infections

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

Dapivirine Phase III trial now underway in Africa to treat HIV in women

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

Insight into possible new approaches in vaccine development for blood-borne infections and HIV

Scientists discover structure and operating procedures of anti-bacterial killing machine

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News